109 related articles for article (PubMed ID: 36511379)
1. A novel immunotherapy prognostic score for patients with pretreated advanced urInary TrAct CArcinoma from the subgroup analysis of the SAUL study: the ITACA Score.
Fornarini G; Rebuzzi SE; Buti S; Rescigno P; Merseburger A; Sternberg CN; de Giorgi U; Basso U; Maruzzo M; Giannatempo P; Ponzano M; Giunta EF; Catalano F; Murianni V; Damassi A; Cremante M; Gandini A; Puglisi S; Llaja Obispo MA; Signori A; Banna GL
Minerva Urol Nephrol; 2023 Jun; 75(3):308-318. PubMed ID: 36511379
[TBL] [Abstract][Full Text] [Related]
2. New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitors.
Bamias A; Merseburger A; Loriot Y; James N; Choy E; Castellano D; Lopez-Rios F; Calabrò F; Kramer M; de Velasco G; Zakopoulou R; Tzannis K; Sternberg CN
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36627145
[TBL] [Abstract][Full Text] [Related]
3. Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract.
Sternberg CN; Loriot Y; James N; Choy E; Castellano D; Lopez-Rios F; Banna GL; De Giorgi U; Masini C; Bamias A; Garcia Del Muro X; Duran I; Powles T; Gamulin M; Zengerling F; Geczi L; Gedye C; de Ducla S; Fear S; Merseburger AS
Eur Urol; 2019 Jul; 76(1):73-81. PubMed ID: 30910346
[TBL] [Abstract][Full Text] [Related]
4. Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort.
Fornarini G; Rebuzzi SE; Banna GL; Calabrò F; Scandurra G; De Giorgi U; Masini C; Baldessari C; Naglieri E; Caserta C; Manacorda S; Maruzzo M; Milella M; Buttigliero C; Tambaro R; Ermacora P; Morelli F; Nolè F; Astolfi C; Sternberg CN
ESMO Open; 2021 Jun; 6(3):100118. PubMed ID: 33984678
[TBL] [Abstract][Full Text] [Related]
5. SAUL, a single-arm study of atezolizumab for chemotherapy-pretreated locally advanced or metastatic carcinoma of the urinary tract: outcomes by key baseline factors, PD-L1 expression and prior platinum therapy.
Bamias A; Merseburger AS; Loriot Y; James N; Choy E; Castellano D; Lopez-Rios F; Calabrò F; Kramer M; de Velasco G; Zakopoulou R; Tzannis K; Sternberg CN
ESMO Open; 2021 Jun; 6(3):100152. PubMed ID: 33984672
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Value of the Lung Immune Prognosis Index Score for Patients Treated with Immune Checkpoint Inhibitors for Advanced or Metastatic Urinary Tract Carcinoma.
Parent P; Auclin E; Patrikidou A; Mezquita L; Martínez Chanzá N; Dumont C; Rodriguez-Vida A; Llacer C; Lozano R; Ratta R; Merseburger AS; Sternberg CN; Baciarello G; Colomba E; Fuerea A; Besse B; Loriot Y; Lavaud P
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831409
[TBL] [Abstract][Full Text] [Related]
7. Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study).
Rebuzzi SE; Signori A; Banna GL; Maruzzo M; De Giorgi U; Pedrazzoli P; Sbrana A; Zucali PA; Masini C; Naglieri E; Procopio G; Merler S; Tomasello L; Fratino L; Baldessari C; Ricotta R; Panni S; Mollica V; Sorarù M; Santoni M; Cortellini A; Prati V; Soto Parra HJ; Stellato M; Atzori F; Pignata S; Messina C; Messina M; Morelli F; Prati G; Nolè F; Vignani F; Cavo A; Roviello G; Pierantoni F; Casadei C; Bersanelli M; Chiellino S; Paolieri F; Perrino M; Brunelli M; Iacovelli R; Porta C; Buti S; Fornarini G
Ther Adv Med Oncol; 2021; 13():17588359211019642. PubMed ID: 34046089
[TBL] [Abstract][Full Text] [Related]
8. Enhanced Bellmunt Risk Score for Survival Prediction in Urothelial Carcinoma Treated With Immunotherapy.
Abuhelwa AY; Bellmunt J; Kichenadasse G; McKinnon RA; Rowland A; Sorich MJ; Hopkins AM
Clin Genitourin Cancer; 2022 Apr; 20(2):132-138. PubMed ID: 34953754
[TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of Atezolizumab in Understudied Populations with Pretreated Urinary Tract Carcinoma: Subgroup Analyses of the SAUL Study in Real-World Practice.
Merseburger AS; Castellano D; Powles T; Loriot Y; Retz M; Voortman J; Huddart RA; Gedye C; Van Der Heijden MS; Gurney H; Ong M; de Ducla S; Pavlova J; Fear S; Sternberg CN
J Urol; 2021 Aug; 206(2):240-251. PubMed ID: 33835866
[TBL] [Abstract][Full Text] [Related]
10. Swiss experience of atezolizumab for platinum-pretreated urinary tract carcinoma: the SAUL study in real-world practice.
Cathomas R; Schardt J; Pless M; Llado A; Mach N; Riklin C; Haefeli J; Fear S; Stenner F
Swiss Med Wkly; 2020 May; 150():w20223. PubMed ID: 32399958
[TBL] [Abstract][Full Text] [Related]
11. Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score).
Bigot F; Castanon E; Baldini C; Hollebecque A; Carmona A; Postel-Vinay S; Angevin E; Armand JP; Ribrag V; Aspeslagh S; Varga A; Bahleda R; Menis J; Gazzah A; Michot JM; Marabelle A; Soria JC; Massard C
Eur J Cancer; 2017 Oct; 84():212-218. PubMed ID: 28826074
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of atezolizumab in patients with autoimmune disease: Subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma.
Loriot Y; Sternberg CN; Castellano D; Oosting SF; Dumez H; Huddart R; Vianna K; Alonso Gordoa T; Skoneczna I; Fay AP; Nolè F; Massari F; Brasiuniene B; Maroto P; Fear S; Di Nucci F; de Ducla S; Choy E
Eur J Cancer; 2020 Oct; 138():202-211. PubMed ID: 32905959
[TBL] [Abstract][Full Text] [Related]
13. Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials.
Alhalabi O; Hahn AW; Msaouel P; Meric-Bernstam F; Wilson N; Naing A; Piha-Paul S; Janku F; Pant S; Yap TA; Hong DS; Fu S; Karp D; Beltran K; Campbell E; Le H; Campbell MT; Shah A; Tannir NM; Siefker-Radtke A; Gao J; Roszik J; Subbiah V
Clin Genitourin Cancer; 2022 Feb; 20(1):e16-e24. PubMed ID: 34362693
[TBL] [Abstract][Full Text] [Related]
14. EPSILoN: A Prognostic Score Using Clinical and Blood Biomarkers in Advanced Non-Small-cell Lung Cancer Treated With Immunotherapy.
Prelaj A; Rebuzzi SE; Pizzutilo P; Bilancia M; Montrone M; Pesola F; Longo V; Del Bene G; Lapadula V; Cassano F; Petrillo P; Bafunno D; Varesano N; Lamorgese V; Mastrandrea A; Ricci D; Catino A; Galetta D
Clin Lung Cancer; 2020 Jul; 21(4):365-377.e5. PubMed ID: 32245624
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens.
Bellmunt J; Choueiri TK; Fougeray R; Schutz FA; Salhi Y; Winquist E; Culine S; von der Maase H; Vaughn DJ; Rosenberg JE
J Clin Oncol; 2010 Apr; 28(11):1850-5. PubMed ID: 20231682
[TBL] [Abstract][Full Text] [Related]
16. A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9-15 PROMISE-meso phase III trial.
Banna GL; Addeo A; Zygoura P; Tsourti Z; Popat S; Curioni-Fontecedro A; Nadal E; Shah R; Pope A; Fisher P; Spicer J; Roy A; Gilligan D; Gautschi O; Janthur WD; López-Castro R; Roschitzki-Voser H; Dafni U; Peters S; Stahel RA
Lung Cancer; 2022 Jul; 169():77-83. PubMed ID: 35660972
[TBL] [Abstract][Full Text] [Related]
17. Biological Rationale for Peripheral Blood Cell-Derived Inflammatory Indices and Related Prognostic Scores in Patients with Advanced Non-Small-Cell Lung Cancer.
Banna GL; Friedlaender A; Tagliamento M; Mollica V; Cortellini A; Rebuzzi SE; Prelaj A; Naqash AR; Auclin E; Garetto L; Mezquita L; Addeo A
Curr Oncol Rep; 2022 Dec; 24(12):1851-1862. PubMed ID: 36255605
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors in patients with metastatic urothelial carcinoma who have treated with Atezolizumab.
Tural D; Ölmez ÖF; Sümbül AT; Özhan N; Çakar B; Köstek O; Ekenel M; Erman M; Coşkun HŞ; Selçukbiricik F; Keskin Ö; Türköz FP; Oruç K; Bayram S; Bilgetekin İ; Yıldız B; Şendur MAN; Paksoy N; Dirican A; Erdem D; Selam M; Tanrıverdi Ö; Paydaş S; Urakçı Z; Atağ E; Güncan S; Ürün Y; Alkan A; Kaya AO; Özyükseler DT; Taşkaynatan H; Yıldırım M; Sönmez M; Başoğlu T; Gündüz Ş; Kılıçkap S; Artaç M
Int J Clin Oncol; 2021 Aug; 26(8):1506-1513. PubMed ID: 34023933
[TBL] [Abstract][Full Text] [Related]
19. An internally validated new clinical and inflammation-based prognostic score for patients with advanced hepatocellular carcinoma treated with sorafenib.
Diaz-Beveridge R; Bruixola G; Lorente D; Caballero J; Rodrigo E; Segura Á; Akhoundova D; Giménez A; Aparicio J
Clin Transl Oncol; 2018 Mar; 20(3):322-329. PubMed ID: 28801777
[TBL] [Abstract][Full Text] [Related]
20. Partial Response and Stable Disease Correlate with Positive Outcomes in Atezolizumab-treated Patients with Advanced Urinary Tract Carcinoma.
Bedke J; Merseburger AS; Loriot Y; Castellano D; Choy E; Duran I; Rosenberg JE; Petrylak DP; Dreicer R; Perez-Gracia JL; Hoffman-Censits JH; Van Der Heijden MS; Pavlova J; Thiebach L; de Ducla S; Fear S; Powles T; Sternberg CN
Eur Urol Focus; 2021 Sep; 7(5):1084-1091. PubMed ID: 33168461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
